| Literature DB >> 27125302 |
Stefan Hacker1,2, Rainer Mittermayr3, Stefanie Nickl1, Thomas Haider2,4, Diana Lebherz-Eichinger2, Lucian Beer2, Andreas Mitterbauer2, Harald Leiss5, Matthias Zimmermann2, Thomas Schweiger2, Claudia Keibl3, Helmut Hofbauer2, Christian Gabriel6, Mariann Pavone-Gyöngyösi7, Heinz Redl3, Erwin Tschachler8, Michael Mildner8, Hendrik Jan Ankersmit2,9.
Abstract
Burn wounds pose a serious threat to patients and often require surgical treatment. Skin grafting aims to achieve wound closure but requires a well-vascularized wound bed. The secretome of peripheral blood mononuclear cells (PBMCs) has been shown to improve wound healing and angiogenesis. We hypothesized that topical application of the PBMC secretome would improve the quality of regenerating skin, increase angiogenesis, and reduce scar formation after burn injury and skin grafting in a porcine model. Full-thickness burn injuries were created on the back of female pigs. Necrotic areas were excised and the wounds were covered with split-thickness mesh skin grafts. Wounds were treated repeatedly with either the secretome of cultured PBMCs (Sec(PBMC)), apoptotic PBMCs (Apo-Sec(PBMC)), or controls. The wounds treated with Apo-Sec(PBMC) had an increased epidermal thickness, higher number of rete ridges, and more advanced epidermal differentiation than controls. The samples treated with Apo-Sec(PBMC) had a two-fold increase in CD31+ cells, indicating more angiogenesis. These data suggest that the repeated application of Apo-Sec(PBMC) significantly improves epidermal thickness, angiogenesis, and skin quality in a porcine model of burn injury and skin grafting.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27125302 PMCID: PMC4850437 DOI: 10.1038/srep25168
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Creation of burn injuries and topical treatment with PBMC secretomes was well tolerated.
(a) Study timeline. (b) A custom-made device was used to create burn wounds on the back of female pigs prior to necrectomy and skin-grafting. (c,d) Routine laboratory parameters showed no signs of infection or anaemia during the study period. Error bars indicate standard error of the mean (SEM). n = 6.
Figure 2Planimetric evaluation of wounds.
Standardized photographs of the wounds were evaluated regarding the open wound area and the ratio of wound contraction using ImageJ software on postoperative day 0 (a,b) and day 10 (c). The white areas indicate the open wound immediately after surgery. (d) The extent of the open wound area was comparable between all groups on day 10. (e) The wounds treated with Apo-SecPBMC had a trend towards reduced wound contraction rate on day 10 compared to the medium control group. (f) Re-epithelialization rates on days 2, 5 and 10 are shown. Error bars indicate standard error of the mean (SEM). n = 6
Figure 3Secretome treatment improves skin quality and epidermal differentiation.
Representative H&E staining of the wound edges taken from areas treated with NaCl (a), medium (b), SecPBMC (c), and Apo-SecPBMC (d). The small inserted sections show the corresponding stainings for the epidermal differentiation marker keratin-10. A progressed epidermal differentiation was observed after treatment with SecPBMC and Apo-SecPBMC compared to the control groups. The asterisk (*) indicates the wounded side; the other side shows the healthy, unburned skin. 100× magnification, scale bar: 100 μm. (e) The epidermal thickness was markedly increased in the Apo-SecPBMC group. (f) The development of rete ridges – as indicated by a higher ratio between the length of the inner and outer epidermal border – was significantly increased in wounds treated with either SecPBMC or Apo-SecPBMC compared to NaCl and medium controls. Error bars indicate SEM. n = 6. Healthy skin: n = 4.
Figure 4Increased numbers of CD31+ and ASMA cells were observed in wounds treated with PBMC secretomes.
Punch biopsy sections taken on day 5 were stained for the angiogenesis marker CD31. Representative samples of the NaCl (a), medium (b), SecPBMC (c) and Apo-SecPBMC (d) treated wounds are shown. 200× magnification, scale bar: 50 μm. The quantification of CD31+ cells was performed on four randomly selected sections per wound. The numbers correspond to the total amount of cells over four sections. (e) Treatment with Apo-SecPBMC led to a significant two-fold increase in CD31+ cells compared to the control groups. (f) Mature blood vessels (ASMA+ cells) were more frequent in the wounds treated with both SecPBMC and Apo- SecPBMC compared to the control groups, respectively. Error bars indicate SEM. n = 6.
Figure 5Mast cell counts are reduced after SecPBMC and Apo-SecPBMC treatment.
Mast cells are found in wounds if derailed scarring occurs. (a) Mast cell tryptase-positive cells were found in the superficial layers of the dermis. Arrows indicate mast cells. 400× magnification, scale bar: 50 μm. (b) We found no difference in mast cell numbers 2 days after surgery. (c) On day 5 we observed a non-significant trend towards fewer mast cells in wounds treated with SecPBMC or Apo-SecPBMC compared to the control groups. (d) On day 10, this difference was more pronounced. The numbers in the diagrams represent the sum of four randomly chosen sections per wound. Error bars indicate SEM. n = 6.
Results of biomechanical wound measurements using the BTC-2000™ system are shown.
| NaCl | Medium | SecPBMC | Apo-SecPBMC | |||||
|---|---|---|---|---|---|---|---|---|
| mean | SD | mean | SD | mean | SD | mean | SD | |
| Laxity (%) | 28.23 | 6.66 | 30.67 | 16.69 | 17.02 | 12.85 | 38.25 | 17.01 |
| Elastic Deformation (mm) | 1.87 | 0.54 | 1.85 | 0.33 | 1.76 | 0.40 | 2.14 | 0.43 |
| Stiffness (mmHg) | 93.58 | 28.17 | 88.34 | 12.83 | 90.46 | 12.73 | 78.91 | 18.02 |
| Energy Absorption (mmHg x mm) | 125.44 | 34.16 | 124.65 | 19.17 | 122.22 | 20.03 | 145.50 | 33.56 |
| Elasticity (%) | 43.18 | 13.83 | 40.62 | 9.23 | 46.33 | 26.96 | 39.20 | 7.83 |